Peripheral Nerves in Cancer: Regulatory Roles and Therapeutic Strategies

Abstract

Cancer neuroscience has emerged as a transformative frontier in oncology research, focusing on the interplay between cancer cells and the nervous system. Cancer cells establish tumorspecific neural networks within tumor tissues via neurotrophic hijacking. The nervous system regulates tumor initiation, progression, and metastasis either directly by regulating signal transduction in tumor cells or indirectly by modulating the tumor microenvironment (TME). The positive feedback loop between cancer cells and nerves promotes tumor progression. Deciphering the regulatory role of nerves in tumor progression may yield novel anticancer therapeutic options. In this review, the interaction between nerves and cancer cells is described, including how cancer cells hijack and remodel nervous system structure and function, and how neuron-signaling regulates cancer cell growth directly or indirectly through modulating the TME. This evidence of the critical role of nerves in the malignant phenotype of tumors indicates the potential of using neuron-signaling targeting strategies in cancer treatment. By summarizing these findings, this review aims to provide comprehensive insights into the interaction between nerves and cancer cells, paving the way for neuron-signaling-based anticancer therapies.

Keywords

cancer / interaction / mechanism / nerve / therapeutic strategies

References

[1] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229–263.

[2] A. Sinha, D. Ghosh, and D. Karati, “Tumor Microenvironment and Immunotherapy: From Bench to Bedside,” Medical Oncology 42, no. 7 (2025): 244.

[3] J. G. Batsakis, “Nerves and Neurotropic Carcinomas,” Annals of Otology, Rhinology and Laryngology 94, no. 4 Pt 1 (1985): 426–427.

[4] C. Liebig, G. Ayala, J. A. Wilks, D. H. Berger, and D. Albo, “Perineural Invasion in Cancer: A Review of the Literature,” Cancer 115, no. 15 (2009): 3379–3391.

[5] M. Amit, Y. Binenbaum, L. Trejo-Leider, et al., “International Collaborative Validation of Intraneural Invasion as a Prognostic Marker in Adenoid Cystic Carcinoma of the Head and Neck,” Head & Neck 37, no. 7 (2015): 1038–1045.

[6] C. Magnon, S. J. Hall, J. Lin, et al., “Autonomic Nerve Development Contributes to Prostate Cancer Progression,” Science 341, no. 6142 (2013): 1236361.

[7] C. M. Zhao, Y. Hayakawa, Y. Kodama, et al., “Denervation Suppresses Gastric Tumorigenesis,” Science Translational Medicine 6, no. 250 (2014): 250ra115.

[8] J. L. Saloman, K. M. Albers, D. Li, et al., “Ablation of Sensory Neurons in a Genetic Model of Pancreatic Ductal Adenocarcinoma Slows Initiation and Progression of Cancer,” Proceedings National Academy of Science of the United States of America 113, no. 11 (2016): 3078–3083.

[9] J. Pundavela, S. Roselli, S. Faulkner, et al., “Nerve Fibers Infiltrate the Tumor Microenvironment and Are Associated With Nerve Growth Factor Production and Lymph Node Invasion in Breast Cancer,” Mol Oncol 9, no. 8 (2015): 1626–1635.

[10] Z. Dubeykovskaya, Y. Si, X. Chen, et al., “Neural Innervation Stimulates Splenic TFF2 to Arrest Myeloid Cell Expansion and Cancer,” Nature Communications 7 (2016): 10517.

[11] M. Madeo, P. L. Colbert, D. W. Vermeer, et al., “Cancer Exosomes Induce Tumor Innervation,” Nature Communications 9, no. 1 (2018): 4284.

[12] Y. Fu, K. Shen, H. Wang, et al., “Alpha5 nicotine Acetylcholine Receptor Subunit Promotes Intrahepatic Cholangiocarcinoma Metastasis,” Signal Transduct Target Ther 9, no. 1 (2024): 63.

[13] S. Faulkner, P. Jobling, B. March, C. C. Jiang, and H. Hondermarck, “Tumor Neurobiology and the War of Nerves in Cancer,” Cancer Discovery 9, no. 6 (2019): 702–710.

[14] M. Monje, J. C. Borniger, N. J. D'Silva, et al., “Roadmap for the Emerging Field of Cancer Neuroscience,” Cell 181, no. 2 (2020): 219–222.

[15] M. Wang, N. Pu, X. Bo, F. Chen, Y. Zhou, and Q. Cheng, “Significance and Mechanisms of Perineural Invasion in Malignant Tumors,” Frontiers in Oncology 15 (2025): 1572396.

[16] N. A. A. Ebrahim, S. M. A. Soliman, M. O. Othman, and N. S. Tahoun, “Molecular Mechanisms and Clinical Significance of Perineural Invasion in Malignancies: The Pivotal Role of Tumor-associated Schwann Cells in Cancer Progression and Metastasis,” Medical Oncology 42, no. 5 (2025): 171.

[17] G. D. Dodd, P. A. Dolan, A. J. Ballantyne, M. L. Ibanez, and P. Chau, “The Dissemination of Tumors of the Head and Neck via the Cranial Nerves,” Radiologic Clinics of North America 8, no. 3 (1970): 445–461.

[18] M. O. Hassan and J. Maksem, “The Prostatic Perineural Space and Its Relation to Tumor Spread: An Ultrastructural Study,” American Journal of Surgical Pathology 4, no. 2 (1980): 143–148.

[19] D. A. Tuveson, A. T. Shaw, N. A. Willis, et al., “Endogenous Oncogenic K-ras(G12D) Stimulates Proliferation and Widespread Neoplastic and Developmental Defects,” Cancer Cell 5, no. 4 (2004): 375–387.

[20] C. S. Scanlon, R. Banerjee, R. C. Inglehart, et al., “Galanin Modulates the Neural Niche to Favour Perineural Invasion in Head and Neck Cancer,” Nature Communications 6 (2015): 6885.

[21] G. E. Ayala, H. Dai, S. A. Tahir, et al., “Stromal Antiapoptotic Paracrine Loop in Perineural Invasion of Prostatic Carcinoma,” Cancer Research 66, no. 10 (2006): 5159–5164.

[22] G. E. Ayala, H. Dai, M. Ittmann, et al., “Growth and Survival Mechanisms Associated With Perineural Invasion in Prostate Cancer,” Cancer Research 64, no. 17 (2004): 6082–6090.

[23] T. De Oliveira, I. Abiatari, S. Raulefs, et al., “Syndecan-2 Promotes Perineural Invasion and Cooperates With K-ras to Induce an Invasive Pancreatic Cancer Cell Phenotype,” Molecular Cancer 11 (2012): 19.

[24] I. Abiatari, T. DeOliveira, V. Kerkadze, et al., “Consensus Transcriptome Signature of Perineural Invasion in Pancreatic Carcinoma,” Molecular Cancer Therapeutics 8, no. 6 (2009): 1494–1504.

[25] H. Yuan, Y. Zhang, F. Liu, et al., “Exploring the Biological Mechanism and Clinical Value of Perineural Invasion in Pancreatic Cancer,” Cancer Letters 613 (2025): 217515.

[26] L. L. Zhai, Y. Wu, C. Y. Cai, and Z. G. Tang, “Upregulated Matrix Metalloproteinase-2 and Downregulated Tissue Factor Pathway Inhibitor-2 Are Risk Factors for Lymph Node Metastasis and Perineural Invasion in Pancreatic Carcinoma,” Onco Targets Ther 8 (2015): 2827–2834.

[27] C. Huang, Y. Li, Y. Guo, et al., “MMP1/PAR1/SP/NK1R Paracrine Loop Modulates Early Perineural Invasion of Pancreatic Cancer Cells,” Theranostics 8, no. 11 (2018): 3074–3086.

[28] I. C. Sroka, H. Chopra, L. Das, J. M. Gard, R. B. Nagle, and A. E. Cress, “Schwann Cells Increase Prostate and Pancreatic Tumor Cell Invasion Using Laminin Binding A6 Integrin,” Journal of Cellular Biochemistry 117, no. 2 (2016): 491–499.

[29] B. Han, X. Guan, M. Ma, et al., “Stiffened Tumor Microenvironment Enhances Perineural Invasion in Breast Cancer via Integrin Signaling,” Cell Oncol (Dordr) 47, no. 3 (2024): 867–882.

[30] M. Coulpier, J. Anders, and C. F. Ibáñez, “Coordinated Activation of Autophosphorylation Sites in the RET Receptor Tyrosine Kinase: Importance of Tyrosine 1062 for GDNF Mediated Neuronal Differentiation and Survival,” Journal of Biological Chemistry 277, no. 3 (2002): 1991–1999.

[31] F. Marchesi, L. Piemonti, G. Fedele, et al., “The Chemokine Receptor CX3CR1 Is Involved in the Neural Tropism and Malignant Behavior of Pancreatic Ductal Adenocarcinoma,” Cancer Research 68, no. 21 (2008): 9060–9069.

[32] S. He, S. He, C. H. Chen, et al., “The Chemokine (CCL2-CCR2) Signaling Axis Mediates Perineural Invasion,” Molecular Cancer Research 13, no. 2 (2015): 380–390.

[33] O. Cavel, O. Shomron, A. Shabtay, et al., “Endoneurial Macrophages Induce Perineural Invasion of Pancreatic Cancer Cells by Secretion of GDNF and Activation of RET Tyrosine Kinase Receptor,” Cancer Research 72, no. 22 (2012): 5733–5743.

[34] M. Amit, S. Na'ara, L. Leider-Trejo, et al., “Upregulation of RET Induces Perineurial Invasion of Pancreatic Adenocarcinoma,” Oncogene 36, no. 23 (2017): 3232–3239.

[35] X. Li, X. Yang, S. Lin, et al., “Perineural Invasion in Cervical Cancer,” Cancer Letters 616 (2025): 217561.

[36] M. Fujimoto, R. Kitazawa, S. Maeda, and S. Kitazawa, “Methylation Adjacent to Negatively Regulating AP-1 Site Reactivates TrkA Gene Expression During Cancer Progression,” Oncogene 24, no. 32 (2005): 5108–5118.

[37] A. A. Geldof, M. A. De Kleijn, B. R. Rao, and D. W. Newling, “Nerve Growth Factor Stimulates in Vitro Invasive Capacity of DU145 human Prostatic Cancer Cells,” Journal of Cancer Research and Clinical Oncology 123, no. 2 (1997): 107–112.

[38] J. Ma, Y. Jiang, Y. Jiang, Y. Sun, and X. Zhao, “Expression of Nerve Growth Factor and Tyrosine Kinase Receptor A and Correlation With Perineural Invasion in Pancreatic Cancer,” Journal of Gastroenterology and Hepatology 23, no. 12 (2008): 1852–1859.

[39] J. L. Saloman, A. D. Singhi, D. J. Hartman, D. P. Normolle, K. M. Albers, and B. M. Davis, “Systemic Depletion of Nerve Growth Factor Inhibits Disease Progression in a Genetically Engineered Model of Pancreatic Ductal Adenocarcinoma,” Pancreas 47, no. 7 (2018): 856–863.

[40] S. He, C. H. Chen, N. Chernichenko, et al., “GFRα1 released by Nerves Enhances Cancer Cell Perineural Invasion Through GDNF-RET Signaling,” PNAS 111, no. 19 (2014): E2008–E2017.

[41] F. Carlomagno, D. Vitagliano, T. Guida, et al., “The Kinase Inhibitor PP1 Blocks Tumorigenesis Induced by RET Oncogenes,” Cancer Research 62, no. 4 (2002): 1077–1082.

[42] Y. Chen, W. Zhang, Y. Zeng, et al., “GDNF-induced Phosphorylation of MUC21 Promotes Pancreatic Cancer Perineural Invasion and Metastasis by Activating RAC2 GTPase,” Oncogene 43, no. 34 (2024): 2564–2577.

[43] G. M. Sclabas, S. Fujioka, C. Schmidt, et al., “Overexpression of Tropomysin-related Kinase B in Metastatic human Pancreatic Cancer Cells,” Clinical Cancer Research 11, no. 2 Pt 1 (2005): 440–449.

[44] Y. J. Feng, B. Y. Zhang, R. Y. Yao, and Y. Lu, “Muscarinic Acetylcholine Receptor M3 in Proliferation and Perineural Invasion of Cholangiocarcinoma Cells,” Hepatobiliary & Pancreatic Diseases International 11, no. 4 (2012): 418–423.

[45] J. Bauman and K. McVary, “Autonomic Nerve Development Contributes to Prostate Cancer Progression,” Asian Journal of Andrology 15, no. 6 (2013): 713–714.

[46] F. Entschladen, D. TLt, K. Lang, J. Joseph, and K. S. Zaenker, “Tumour-cell Migration, Invasion, and Metastasis: Navigation by Neurotransmitters,” The Lancet Oncology 5, no. 4 (2004): 254–258.

[47] K. Guo, Q. Ma, J. Li, et al., “Interaction of the Sympathetic Nerve With Pancreatic Cancer Cells Promotes Perineural Invasion Through the Activation of STAT3 Signaling,” Molecular Cancer Therapeutics 12, no. 3 (2013): 264–273.

[48] S. Zheng, C. Hu, Q. Lin, et al., “Extracellular Vesicle-packaged PIAT From Cancer-associated Fibroblasts Drives Neural Remodeling by Mediating m5C Modification in Pancreatic Cancer Mouse Models,” Science Translational Medicine 16, no. 756 (2024): eadi0178.

[49] T. Li, C. Hu, T. Huang, et al., “Cancer-Associated Fibroblasts Foster a High-Lactate Microenvironment to Drive Perineural Invasion in Pancreatic Cancer,” Cancer Research 85, no. 12 (2025): 2199–2217.

[50] M. V. Apte, J. S. Wilson, A. Lugea, and S. J. Pandol, “A Starring Role for Stellate Cells in the Pancreatic Cancer Microenvironment,” Gastroenterology 144, no. 6 (2013): 1210–1219.

[51] I. E. Demir, A. Boldis, P. L. Pfitzinger, et al., “Investigation of Schwann Cells at Neoplastic Cell Sites Before the Onset of Cancer Invasion,” JNCI: Journal of the National Cancer Institute 106, no. 8 (2014).

[52] X. Li, Z. Wang, Q. Ma, et al., “Sonic Hedgehog Paracrine Signaling Activates Stromal Cells to Promote Perineural Invasion in Pancreatic Cancer,” Clinical Cancer Research 20, no. 16 (2014): 4326–4338.

[53] A. Vonlaufen, S. Joshi, C. Qu, et al., “Pancreatic Stellate Cells: Partners in Crime With Pancreatic Cancer Cells,” Cancer Research 68, no. 7 (2008): 2085–2093.

[54] G. E. Ayala, T. M. Wheeler, H. D. Shine, et al., “In Vitro Dorsal Root Ganglia and human Prostate Cell Line Interaction: Redefining Perineural Invasion in Prostate Cancer,” Prostate 49, no. 3 (2001): 213–223.

[55] G. E. Ayala, H. Dai, M. Powell, et al., “Cancer-related Axonogenesis and Neurogenesis in Prostate Cancer,” Clinical Cancer Research 14, no. 23 (2008): 7593–7603.

[56] A. H. Zahalka, A. Arnal-Estapé, M. Maryanovich, et al., “Adrenergic Nerves Activate an Angio-metabolic Switch in Prostate Cancer,” Science 358, no. 6361 (2017): 321–326.

[57] L. B. Schmitd, L. J. Beesley, N. Russo, et al., “Redefining Perineural Invasion: Integration of Biology with Clinical Outcome,” Neoplasia 20, no. 7 (2018): 657–667.

[58] A. Kovacs, D. W. Vermeer, M. Madeo, S. J. Vermeer, and P. D. Vermeer. Tumor-infiltrating nerves create an electro-physiologically active microenvironment and contribute to treatment resistance. bioRxiv. 2020.

[59] K. Servick, “War of Nerves,” Science 365, no. 6458 (2019): 1071–1073.

[60] H. D. Reavis, H. I. Chen, and R. Drapkin, “Tumor Innervation: Cancer Has some Nerve,” Trends in cancer 6, no. 12 (2020): 1059–1067.

[61] P. Mauffrey, N. Tchitchek, V. Barroca, et al., “Progenitors From the central Nervous System Drive Neurogenesis in Cancer,” Nature 569, no. 7758 (2019): 672–678.

[62] D. Zhang, D. Park, Y. Zhong, et al., “Stem Cell and Neurogenic Gene-expression Profiles Link Prostate Basal Cells to Aggressive Prostate Cancer,” Nature Communications 7 (2016): 10798.

[63] R. Lu, C. Fan, W. Shangguan, et al., “Neurons Generated From Carcinoma Stem Cells Support Cancer Progression,” Signal Transduct Target Ther 2 (2017): 16036.

[64] C. J. Emmett, P. A. McNeeley, and R. M. Johnson, “Evaluation of human Astrocytoma and Glioblastoma Cell Lines for Nerve Growth Factor Release,” Neurochemistry International 30, no. 4-5 (1997): 465–474.

[65] J. Pundavela, Y. Demont, P. Jobling, et al., “ProNGF Correlates With Gleason Score and Is a Potential Driver of Nerve Infiltration in Prostate Cancer,” American Journal of Pathology 184, no. 12 (2014): 3156–3162.

[66] B. W. Renz, R. Takahashi, T. Tanaka, et al., “β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer,” Cancer Cell 33, no. 1 (2018): 75–90.e7.

[67] Y. Hayakawa, K. Sakitani, M. Konishi, et al., “Nerve Growth Factor Promotes Gastric Tumorigenesis Through Aberrant Cholinergic Signaling,” Cancer Cell 31, no. 1 (2017): 21–34.

[68] B. W. Renz, R. Takahashi, T. Tanaka, et al., “β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer,” Cancer Cell 34, no. 5 (2018): 863–867.

[69] J. K. Allen, G. N. Armaiz-Pena, A. S. Nagaraja, et al., “Sustained Adrenergic Signaling Promotes Intratumoral Innervation Through BDNF Induction,” Cancer Research 78, no. 12 (2018): 3233–3242.

[70] Y. Ding, D. He, D. Florentin, et al., “Semaphorin 4F as a Critical Regulator of Neuroepithelial Interactions and a Biomarker of Aggressive Prostate Cancer,” Clinical Cancer Research 19, no. 22 (2013): 6101–6111.

[71] N. R. Jurcak, A. A. Rucki, S. Muth, et al., “Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice,” Gastroenterology 157, no. 3 (2019): 838–850.e6.

[72] R. Kalluri, “The Biology and Function of Extracellular Vesicles in Immune Response and Immunity,” Immunity 57, no. 8 (2024): 1752–1768.

[73] C. T. Lucido, E. Wynja, M. Madeo, et al., “Innervation of Cervical Carcinoma Is Mediated by Cancer-derived Exosomes,” Gynecologic Oncology 154, no. 1 (2019): 228–235.

[74] M. Amit, H. Takahashi, M. P. Dragomir, et al., “Loss of p53 Drives Neuron Reprogramming in Head and Neck Cancer,” Nature 578, no. 7795 (2020): 449–454.

[75] H. H. Young, “On the Presence of Nerves in Tumors and of Other Structures in Them as Revealed by a Modification of ehrlich's Method of , “Vital Staining” With Methylene Blue,” Journal of Experimental Medicine 2, no. 1 (1897): 1–12.

[76] H. Oertel, “Innervation and Tumour Growth: A Preliminary Report,” Canadian Medical Association Journal 18, no. 2 (1928): 135–139.

[77] R. Srinivasan and W. W. Chang, “Effect of Neonatal Sympathectomy on the Postnatal Differentiation of the Submandibular Gland of the Rat,” Cell and Tissue Research 180, no. 1 (1977): 99–109.

[78] T. C. Muir, D. Pollock, and C. J. Turner, “The Effects of Electrical Stimulation of the Autonomic Nerves and of Drugs on the Size of Salivary Glands and Their Rate of Cell Division,” Journal of Pharmacology and Experimental Therapeutics 195, no. 2 (1975): 372–381.

[79] H. Dai, R. Li, T. Wheeler, et al., “Enhanced Survival in Perineural Invasion of Pancreatic Cancer: An in Vitro Approach,” Human Pathology 38, no. 2 (2007): 299–307.

[80] S. H. Jiang, L. P. Hu, X. Wang, J. Li, and Z. G. Zhang, “Neurotransmitters: Emerging Targets in Cancer,” Oncogene 39, no. 3 (2020): 503–515.

[81] B. M. Evers, “Neurotensin and Growth of Normal and Neoplastic Tissues,” Peptides 27, no. 10 (2006):2424–2433.

[82] G. Kyriatzis, M. Khrestchatisky, L. Ferhat, and E. A. Chatzaki, “Neurotensin and Neurotensin Receptors in Stress-related Disorders: Pathophysiology & Novel Drug Targets,” Current Neuropharmacology 22, no. 5 (2024): 916–934.

[83] F. Ghaemimanesh, M. Mehravar, S. Milani, E. M. Poursani, and K. Saliminejad, “The Multifaceted Role of Sortilin/Neurotensin Receptor 3 in human Cancer Development,” Journal of Cellular Physiology 236, no. 9 (2021): 6271–6281.

[84] Y. H. Hung, H. C. Wang, S. H. Hsu, et al., “Neuron-derived Neurotensin Promotes Pancreatic Cancer Invasiveness and Gemcitabine Resistance via the NTSR1/Akt Pathway,” Am J Cancer Res 14, no. 2 (2024): 448–466.

[85] N. Bertrand, R. Mougel, G. Riley, M. Bruand, G. Gauchotte, and M. Agopiantz, “Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers,” International Journal of Molecular Sciences 25, no. 21 (2024).

[86] S. Nikolaou, S. Qiu, F. Fiorentino, et al., “The Role of Neurotensin and Its Receptors in Non-gastrointestinal Cancers: A Review,” Cell Communication and Signaling 18, no. 1 (2020): 68.

[87] Z. K. Dong, Y. F. Wang, W. P. Li, and W. L. Jin, “Neurobiology of Cancer: Adrenergic Signaling and Drug Repurposing,” Pharmacology & Therapeutics 264 (2024): 108750.

[88] M. H. Antoni, S. K. Lutgendorf, S. W. Cole, et al., “The Influence of Bio-behavioural Factors on Tumour Biology: Pathways and Mechanisms,” Nature Reviews Cancer 6, no. 3 (2006): 240–248.

[89] P. H. Thaker, L. Y. Han, A. A. Kamat, et al., “Chronic Stress Promotes Tumor Growth and Angiogenesis in a Mouse Model of Ovarian Carcinoma,” Nature Medicine 12, no. 8 (2006): 939–944.

[90] P. H. Thaker, L. Y. Han, A. A. Kamat, et al., “Author Correction: Chronic Stress Promotes Tumor Growth and Angiogenesis in a Mouse Model of Ovarian Carcinoma,” Nature Medicine 27, no. 12 (2021): 2246.

[91] Z. Chen, Y. Zhou, C. Xue, et al., “Psychological Stress-induced ALKBH5 Deficiency Promotes Tumour Innervation and Pancreatic Cancer via Extracellular Vesicle Transfer of RNA,” Nature Cell Biology 27, no. 6 (2025): 1035–1047.

[92] L. I. Partecke, S. Speerforck, A. Käding, et al., “Chronic Stress Increases Experimental Pancreatic Cancer Growth, Reduces Survival and Can be Antagonised by Beta-adrenergic Receptor Blockade,” Pancreatology 16, no. 3 (2016): 423–433.

[93] S. Hassan, Y. Karpova, D. Baiz, et al., “Behavioral Stress Accelerates Prostate Cancer Development in Mice,” Journal of Clinical Investigation 123, no. 2 (2013): 874–886.

[94] H. M. Schuller, H. A. Al-Wadei, M. F. Ullah, and H. K. Plummer 3rd, “Regulation of Pancreatic Cancer by Neuropsychological Stress Responses: A Novel Target for Intervention,” Carcinogenesis 33, no. 1 (2012): 191–196.

[95] S. Y. Xiong, H. Z. Wen, L. M. Dai, et al., “A Brain-tumor Neural Circuit Controls Breast Cancer Progression in Mice,” Journal of Clinical Investigation 133, no. 24 (2023).

[96] B. Raju, S. R. Haug, S. O. Ibrahim, and K. J. Heyeraas, “Sympathectomy Decreases Size and Invasiveness of Tongue Cancer in Rats,” Neuroscience 149, no. 3 (2007): 715–725.

[97] M. A. Atherton, S. Park, N. L. Horan, et al., “Sympathetic Modulation of Tumor Necrosis Factor Alpha-induced Nociception in the Presence of Oral Squamous Cell Carcinoma,” Pain 164, no. 1 (2023): 27–42.

[98] M. H. Thulin, H. Ramberg, H. K. Nielsen, et al., “Beta-blockers Prolong Response to Androgen Deprivation Therapy in Prostate Cancer Through Modulation of the Neuro-immuno-oncology Axis,” Journal of translational medicine 23, no. 1 (2025): 672.

[99] M. Jin, Y. Wang, T. Zhou, W. Li, and Q. Wen, “Norepinephrine/β(2)-Adrenergic Receptor Pathway Promotes the Cell Proliferation and Nerve Growth Factor Production in Triple-Negative Breast Cancer,” J Breast Cancer 26, no. 3 (2023): 268–285.

[100] S. Zuo, Z. Wang, X. Jiang, et al., “Regulating Tumor Innervation by Nanodrugs Potentiates Cancer Immunochemotherapy and Relieve Chemotherapy-induced Neuropathic Pain,” Biomaterials 309 (2024): 122603.

[101] T. Itami, Y. Kurokawa, T. Hagi, et al., “Sympathetic Innervation Induced by Nerve Growth Factor Promotes Malignant Transformation in Gastric Cancer,” Scientific Reports 15, no. 1 (2025): 3824.

[102] Y. H. Qi, L. Z. Yang, L. Zhou, et al., “Sympathetic Nerve Infiltration Promotes Stomach Adenocarcinoma Progression via Norepinephrine/β2-adrenoceptor/YKL-40 Signaling Pathway,” Heliyon 8, no. 12 (2022): e12468.

[103] H. Kobayashi, T. Iida, Y. Ochiai, et al., “Neuro-mesenchymal Interaction Mediated by a β2 Adrenergic-nerve Growth Factor Feedforward Loop Promotes Colorectal Cancer Progression,” Cancer discovery (2024).

[104] T. Fnu, P. Shi, W. Zhang, et al., “Sympathetic Neurons Promote Small Cell Lung Cancer Through the β2-Adrenergic Receptor,” Cancer discovery 15, no. 3 (2025): 616–632.

[105] Q. Xiao, Y. Liu, T. Li, et al., “Viral Oncogenesis in Cancer: From Mechanisms to Therapeutics,” Signal Transduct Target Ther 10, no. 1 (2025): 151.

[106] S. Huang, D. Lei, L. Yang, et al., “Tumor-Associated Sympathetic Nerves Promote the Progression of Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma,” Adv Sci (Weinh) (2025): e13580.

[107] I. Wessler and C. J. Kirkpatrick, “Acetylcholine Beyond Neurons: The Non-neuronal Cholinergic System in Humans,” British Journal of Pharmacology 154, no. 8 (2008): 1558–1571.

[108] A. B. Carlson and G. P. Kraus, “Physiology, Cholinergic Receptors,” StatPearls. StatPearls Publishing.

[109] Copyright © 2024, StatPearls Publishing LLC.; 2024.

[110] K. R. Keever, V. P. Yakubenko, and D. B. Hoover, “Neuroimmune Nexus in the Pathophysiology and Therapy of Inflammatory Disorders: Role of α7 Nicotinic Acetylcholine Receptors,” Pharmacological Research 191 (2023): 106758.

[111] D. F. Quail and J. A. Joyce, “Microenvironmental Regulation of Tumor Progression and Metastasis,” Nature Medicine 19, no. 11 (2013): 1423–1437.

[112] L. Wang, J. Xu, Y. Xia, et al., “Muscarinic Acetylcholine Receptor 3 Mediates Vagus Nerve-induced Gastric Cancer,” Oncogenesis 7, no. 11 (2018): 88.

[113] Y. E. Park, “Is Vagotomy Necessary in Palliative Surgery for Incurable Advanced Gastric Cancer?: A Retrospective Case-control Study,” World J Surg Oncol 21, no. 1 (2023): 213.

[114] L. I. Partecke, A. Käding, D. N. Trung, et al., “Subdiaphragmatic Vagotomy Promotes Tumor Growth and Reduces Survival via TNFα in a Murine Pancreatic Cancer Model,” Oncotarget 8, no. 14 (2017): 22501–22512.

[115] B. W. Renz, T. Tanaka, M. Sunagawa, et al., “Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness,” Cancer discovery 8, no. 11 (2018): 1458–1473.

[116] L. Zhang, L. Guo, M. Tao, W. Fu, and D. Xiu, “Parasympathetic Neurogenesis Is Strongly Associated With Tumor Budding and Correlates With an Adverse Prognosis in Pancreatic Ductal Adenocarcinoma,” Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 28, no. 2 (2016): 180–186.

[117] C. Schaal, J. Padmanabhan, and S. Chellappan, “The Role of nAChR and Calcium Signaling in Pancreatic Cancer Initiation and Progression,” Cancers (Basel) 7, no. 3 (2015): 1447–1471.

[118] P. C. Hermann, P. Sancho, M. Cañamero, et al., “Nicotine Promotes Initiation and Progression of KRAS-induced Pancreatic Cancer via Gata6-dependent Dedifferentiation of Acinar Cells in Mice,” Gastroenterology 147, no. 5 (2014): 1119–1133. e4.

[119] M. H. Al-Wadei, J. Banerjee, A. L.-W. HA, and H. M. Schuller, “Nicotine Induces Self-renewal of Pancreatic Cancer Stem Cells via Neurotransmitter-driven Activation of Sonic Hedgehog Signalling,” European Journal of Cancer 52 (2016): 188–196.

[120] G. Kang, Y. Jiao, P. Pan, et al., “α5-nAChR/STAT3/CD47 Axis Contributed to Nicotine-related Lung Adenocarcinoma Progression and Immune Escape,” Carcinogenesis 44, no. 10-11 (2023): 773–784.

[121] Y. Fu, H. Ci, W. Du, Q. Dong, and H. Jia, “CHRNA5 Contributes to Hepatocellular Carcinoma Progression by Regulating YAP Activity,” Pharmaceutics 14, no. 2 (2022).

[122] J. Chen, I. W. Y. Cheuk, V. Y. Shin, and A. Kwong, “Acetylcholine Receptors: Key Players in Cancer Development,” Surgical Oncology 31 (2019): 46–53.

[123] S. Afroz, R. Arakaki, T. Iwasa, et al., “CGRP Induces Differential Regulation of Cytokines From Satellite Glial Cells in Trigeminal Ganglia and Orofacial Nociception,” International Journal of Molecular Sciences 20, no. 3 (2019).

[124] S. H. Park, S. Tsuzuki, K. F. Contino, et al., “Crosstalk Between Bone Metastatic Cancer Cells and Sensory Nerves in Bone Metastatic Progression,” Life Sci Alliance 7, no. 12 (2024).

[125] E. S. Schwartz, J. A. Christianson, X. Chen, et al., “Synergistic Role of TRPV1 and TRPA1 in Pancreatic Pain and Inflammation,” Gastroenterology 140, no. 4 (2011): 1283–1291.e1–2.

[126] A. D. Rhim, E. T. Mirek, N. M. Aiello, et al., “EMT and Dissemination Precede Pancreatic Tumor Formation,” Cell 148, no. 1-2 (2012): 349–361.

[127] T. T. Le, S. L. Payne, M. N. Buckwald, et al., “Sensory Nerves Enhance Triple-negative Breast Cancer Invasion and Metastasis via the Axon Guidance Molecule PlexinB3,” NPJ Breast Cancer 8, no. 1 (2022): 116.

[128] S. C. Peterson, M. Eberl, A. N. Vagnozzi, et al., “Basal Cell Carcinoma Preferentially Arises From Stem Cells Within Hair Follicle and Mechanosensory Niches,” Cell Stem Cell 16, no. 4 (2015): 400–412.

[129] Y. Zhang, C. Lin, Z. Liu, et al., “Cancer Cells co-opt Nociceptive Nerves to Thrive in Nutrient-poor Environments and Upon Nutrient-starvation Therapies,” Cell metabolism 34, no. 12 (2022): 1999–2017.e10.

[130] P. Zhu, T. Lu, Z. Chen, et al., “5-hydroxytryptamine Produced by Enteric Serotonergic Neurons Initiates Colorectal Cancer Stem Cell Self-renewal and Tumorigenesis,” Neuron 110, no. 14 (2022): 2268–2282.e4.

[131] H. C. Chen, P. He, M. McDonald, et al., “Histone Serotonylation Regulates Ependymoma Tumorigenesis,” Nature 632, no. 8026 (2024): 903–910.

[132] B. Faubert, A. Solmonson, and R. J. DeBerardinis, “Metabolic Reprogramming and Cancer Progression,” Science 368, no. 6487 (2020).

[133] F. R. Auciello, V. Bulusu, C. Oon, et al., “A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression,” Cancer discovery 9, no. 5 (2019): 617–627.

[134] D. T. Monaghan, R. J. Bridges, and C. W. Cotman, “The Excitatory Amino Acid Receptors: Their Classes, Pharmacology, and Distinct Properties in the Function of the central Nervous System,” Annual Review of Pharmacology and Toxicology 29 (1989): 365–402.

[135] R. S. Banh, D. E. Biancur, K. Yamamoto, et al., “Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer,” Cell 183, no. 5 (2020): 1202–1218.e25.

[136] G. Hoover, S. Gilbert, O. Curley, et al., “Nerve-to-cancer Transfer of Mitochondria During Cancer Metastasis,” Nature (2025).

[137] D. Lambrechts, E. Wauters, B. Boeckx, et al., “Phenotype Molding of Stromal Cells in the Lung Tumor Microenvironment,” Nature Medicine 24, no. 8 (2018): 1277–1289.

[138] S. W. Cole, J. M. Arevalo, R. Takahashi, et al., “Computational Identification of Gene-social Environment Interaction at the human IL6 Locus,” PNAS 107, no. 12 (2010): 5681–5686.

[139] M. M. Shahzad, J. M. Arevalo, G. N. Armaiz-Pena, et al., “Stress Effects on FosB- and Interleukin-8 (IL8)-driven Ovarian Cancer Growth and Metastasis,” Journal of Biological Chemistry 285, no. 46 (2010): 35462–35470.

[140] M. M. K. Shahzad, J. M. Arevalo, G. N. Armaiz-Pena, et al., “Stress Effects on FosB and Interleukin-8 (IL8)-driven Ovarian Cancer Growth and Metastasis,” Journal of Biological Chemistry 293, no. 26 (2018): 10041.

[141] M. W. Yang, L. Y. Tao, Y. S. Jiang, et al., “Perineural Invasion Reprograms the Immune Microenvironment Through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma,” Cancer Research 80, no. 10 (2020): 1991–2003.

[142] H. O. Besedovsky, A. del Rey, E. Sorkin, M. Da Prada, and H. H. Keller, “Immunoregulation Mediated by the Sympathetic Nervous System,” Cellular Immunology 48, no. 2 (1979): 346–355.

[143] E. M. Sternberg, “Neural-immune Interactions in Health and Disease,” Journal of Clinical Investigation 100, no. 11 (1997): 2641–2647.

[144] L. V. Borovikova, S. Ivanova, M. Zhang, et al., “Vagus Nerve Stimulation Attenuates the Systemic Inflammatory Response to Endotoxin,” Nature 405, no. 6785 (2000): 458–462.

[145] H. Wang, M. Yu, M. Ochani, et al., “Nicotinic Acetylcholine Receptor alpha7 Subunit Is an Essential Regulator of Inflammation,” Nature 421, no. 6921 (2003): 384–388.

[146] M. J. Kelly, C. Breathnach, K. J. Tracey, and S. C. Donnelly, “Manipulation of the Inflammatory Reflex as a Therapeutic Strategy,” Cell Rep Med 3, no. 7 (2022): 100696.

[147] H. Salmon, R. Remark, S. Gnjatic, and M. Merad, “Host Tissue Determinants of Tumour Immunity,” Nature Reviews Cancer 19, no. 4 (2019): 215–227.

[148] T. A. Barnes and E. Amir, “HYPE or HOPE: The Prognostic Value of Infiltrating Immune Cells in Cancer,” British Journal of Cancer 118, no. 2 (2018): e5.

[149] T. A. Barnes and E. Amir, “HYPE or HOPE: The Prognostic Value of Infiltrating Immune Cells in Cancer,” British Journal of Cancer 117, no. 4 (2017): 451–460.

[150] Q. Li, S. Xu, Y. Ren, C. Zhang, K. Li, and Y. Liu, “Single-cell RNA Sequencing Reveals adrb1 as a Sympathetic Nerve-regulated Immune Checkpoint Driving T Cell Exhaustion and Impacting Immunotherapy in Esophageal Squamous Cell Carcinoma,” Frontiers in immunology 16 (2025): 1520766.

[151] C. S. Chen, J. Weber, S. J. Holtkamp, et al., “Loss of Direct Adrenergic Innervation After Peripheral Nerve Injury Causes Lymph Node Expansion Through IFN-γ,” Journal of Experimental Medicine 218, no. 8 (2021).

[152] A. M. Globig, S. Zhao, J. Roginsky, et al., “The β(1)-adrenergic Receptor Links Sympathetic Nerves to T Cell Exhaustion,” Nature 622, no. 7982 (2023): 383–392.

[153] M. Balood, M. Ahmadi, T. Eichwald, et al., “Nociceptor Neurons Affect Cancer Immunosurveillance,” Nature 611, no. 7935 (2022): 405–412.

[154] L. B. Darragh, A. Nguyen, T. T. Pham, et al., “Sensory Nerve Release of CGRP Increases Tumor Growth in HNSCC by Suppressing TILs,” Med 5, no. 3 (2024): 254–270.e8.

[155] J. Saravia, N. M. Chapman, and H. Chi, “Helper T Cell Differentiation,” Cell Mol Immunol 16, no. 7 (2019): 634–643.

[156] Y. Hou, L. Sun, M. W. LaFleur, et al., “Neuropeptide Signalling Orchestrates T Cell Differentiation,” Nature 635, no. 8038 (2024): 444–452.

[157] R. Cabrita, M. Lauss, A. Sanna, et al., “Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma,” Nature 577, no. 7791 (2020): 561–565.

[158] B. A. Helmink, S. M. Reddy, J. Gao, et al., “B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response,” Nature 577, no. 7791 (2020): 549–555.

[159] R. Cabrita, M. Lauss, A. Sanna, et al., “Author Correction: Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma,” Nature 580, no. 7801 (2020): E1.

[160] K. Vats, O. Kruglov, B. Sahoo, et al., “Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses,” Cancer immunology research 10, no. 9 (2022): 1141–1154.

[161] J. Yang, G. Chen, R. Wang, C. Song, and H. Yi, “Navigating TAM Receptor Dynamics in Tumour Immunotherapy,” Cancer Immunology, Immunotherapy 74, no. 5 (2025): 146.

[162] A. Etzerodt, M. B. Maniecki, J. H. Graversen, H. J. Møller, V. P. Torchilin, and S. K. Moestrup, “Efficient Intracellular Drug-targeting of Macrophages Using Stealth Liposomes Directed to the Hemoglobin Scavenger Receptor CD163,” J Control Release 160, no. 1 (2012): 72–80.

[163] J. Guillot, C. Dominici, A. Lucchesi, et al., “Sympathetic Axonal Sprouting Induces Changes in Macrophage Populations and Protects Against Pancreatic Cancer,” Nature Communications 13, no. 1 (2022): 1985.

[164] E. K. Sloan, S. J. Priceman, B. F. Cox, et al., “The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast Cancer,” Cancer Research 70, no. 18 (2010): 7042–7052.

[165] S. Yin, J. Wang, Y. Jia, et al., “Sleep Deprivation-induced Sympathetic Activation Promotes Pro-tumoral Macrophage Phenotype via the ADRB2/KLF4 Pathway to Facilitate NSCLC Metastasis,” Iscience 28, no. 5 (2025): 112321.

[166] H. Xiao and K. Yang, “Role of Macrophages in Neuroimmune Regulation,” Frontiers in immunology 16 (2025): 1573174.

[167] K. Bullock and A. Richmond, “Suppressing MDSC Recruitment to the Tumor Microenvironment by Antagonizing CXCR2 to Enhance the Efficacy of Immunotherapy,” Cancers (Basel) 13, no. 24 (2021).

[168] J. Zhu, C. G. Powis de Tenbossche, S. Cané, et al., “Resistance to Cancer Immunotherapy Mediated by Apoptosis of Tumor-infiltrating Lymphocytes,” Nature Communications 8, no. 1 (2017): 1404.

[169] H. Mohammadpour, C. R. MacDonald, G. Qiao, et al., “β2 adrenergic Receptor-mediated Signaling Regulates the Immunosuppressive Potential of Myeloid-derived Suppressor Cells,” Journal of Clinical Investigation 129, no. 12 (2019): 5537–5552.

[170] Q. Xu, Y. Cao, F. Kong, et al., “Multiple Cancer Cell Types Release LIF and Gal3 to Hijack Neural Signals,” Cell Research 34, no. 5 (2024): 345–354.

[171] C. Bottino, V. Picant, E. Vivier, and R. Castriconi, “Natural Killer Cells and Engagers: Powerful Weapons Against Cancer,” Immunological Reviews 328, no. 1 (2024): 412–421.

[172] L. Cao, X. Liu, E. J. Lin, et al., “Environmental and Genetic Activation of a Brain-adipocyte BDNF/Leptin Axis Causes Cancer Remission and Inhibition,” Cell 142, no. 1 (2010): 52–64.

[173] Y. Song, Y. Gan, Q. Wang, et al., “Enriching the Housing Environment for Mice Enhances Their NK Cell Antitumor Immunity via Sympathetic Nerve-Dependent Regulation of NKG2D and CCR5,” Cancer Research 77, no. 7 (2017): 1611–1622.

[174] S. Liu, Z. Wang, Y. Su, et al., “A Neuroanatomical Basis for Electroacupuncture to Drive the Vagal-adrenal Axis,” Nature 598, no. 7882 (2021): 641–645.

[175] S. Liu, Z. Wang, Y. Su, et al., “Author Correction: A Neuroanatomical Basis for Electroacupuncture to Drive the Vagal-adrenal Axis,” Nature 601, no. 7893 (2022): E9.

[176] G. Li, Y. Jiang, H. Tong, et al., “Sciatic Nerve Stimulation Enhances NK Cell Cytotoxicity Through Dopamine Signaling and Synergizes Immunotherapy in Triple-negative Breast Cancer,” Drug Resistance Updates 79 (2025): 101212.

[177] K. Wang, B. Ni, Y. Xie, et al., “Nociceptor Neurons Promote PDAC Progression and Cancer Pain by Interaction With Cancer-associated Fibroblasts and Suppression of Natural Killer Cells,” Cell Research 35, no. 5 (2025): 362–380.

[178] H. W. Kim, S. Wang, A. J. Davies, and S. B. Oh, “The Therapeutic Potential of Natural Killer Cells in Neuropathic Pain,” Trends in Neuroscience (Tins) 46, no. 8 (2023): 617–627.

[179] M. B. Madel and F. Elefteriou, “Mechanisms Supporting the Use of Beta-Blockers for the Management of Breast Cancer Bone Metastasis,” Cancers (Basel) 13, no. 12 (2021).

[180] P. W. Mantyh, “Mechanisms That Drive Bone Pain Across the Lifespan,” British Journal of Clinical Pharmacology 85, no. 6 (2019): 1103–1113.

[181] F. Elefteriou, “Role of Sympathetic Nerves in the Establishment of Metastatic Breast Cancer Cells in Bone,” J Bone Oncol 5, no. 3 (2016): 132–134.

[182] J. P. Campbell, M. R. Karolak, Y. Ma, et al., “Stimulation of Host Bone Marrow Stromal Cells by Sympathetic Nerves Promotes Breast Cancer Bone Metastasis in Mice,” Plos Biology 10, no. 7 (2012): e1001363.

[183] A. M. Decker, Y. Jung, F. C. Cackowski, K. Yumoto, J. Wang, and R. S. Taichman, “Sympathetic Signaling Reactivates Quiescent Disseminated Prostate Cancer Cells in the Bone Marrow,” Molecular Cancer Research 15, no. 12 (2017): 1644–1655.

[184] Z. Guo, X. Jing, X. Sun, S. Sun, Y. Yang, and Y. Cao, “Tumor Angiogenesis and Anti-angiogenic Therapy,” Chinese Medical Journal 137, no. 17 (2024): 2043–2051.

[185] D. M. McDonald and P. Baluk, “Imaging of Angiogenesis in Inflamed Airways and Tumors: Newly Formed Blood Vessels Are Not Alike and May be Wildly Abnormal: Parker B. Francis Lecture,” Chest 128: (2005): 602s–608s.

[186] H. Hashizume, P. Baluk, S. Morikawa, et al., “Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness,” American Journal of Pathology 156, no. 4 (2000): 1363–1380.

[187] B. Larrivée, C. Freitas, S. Suchting, I. Brunet, and A. Eichmann, “Guidance of Vascular Development: Lessons From the Nervous System,” Circulation Research 104, no. 4 (2009): 428–441.

[188] J. M. James and Y. S. Mukouyama, “Neuronal Action on the Developing Blood Vessel Pattern,” Seminars in cell & developmental biology 22, no. 9 (2011): 1019–1027.

[189] Y. Xia, M. Sun, H. Huang, and W. L. Jin, “Drug Repurposing for Cancer Therapy,” Signal Transduct Target Ther 9, no. 1 (2024): 92.

[190] A. Melhem-Bertrandt, M. Chavez-Macgregor, X. Lei, et al., “Beta-blocker Use Is Associated With Improved Relapse-free Survival in Patients With Triple-negative Breast Cancer,” Journal of Clinical Oncology 29, no. 19 (2011): 2645–2652.

[191] R. Udumyan, S. Montgomery, F. Fang, et al., “Beta-Blocker Drug Use and Survival Among Patients With Pancreatic Adenocarcinoma,” Cancer Research 77, no. 13 (2017): 3700–3707.

[192] A. Chang, E. Botteri, R. D. Gillis, et al., “Beta-blockade Enhances Anthracycline Control of Metastasis in Triple-negative Breast Cancer,” Science Translational Medicine 15, no. 693 (2023): eadf1147.

[193] S. Zhou, J. Li, J. Yu, et al., “Tumor Microenvironment Adrenergic Nerves Blockade Liposomes for Cancer Therapy,” J Control Release 351 (2022): 656–666.

[194] K. Y. Fjæstad, A. M. A. Rømer, V. Goitea, et al., “Blockade of Beta-adrenergic Receptors Reduces Cancer Growth and Enhances the Response to Anti-CTLA4 Therapy by Modulating the Tumor Microenvironment,” Oncogene 41, no. 9 (2022): 1364–1375.

[195] K. M. Kokolus, Y. Zhang, J. M. Sivik, et al., “Beta Blocker Use Correlates With Better Overall Survival in Metastatic Melanoma Patients and Improves the Efficacy of Immunotherapies in Mice,” Oncoimmunology 7, no. 3 (2018): e1405205.

[196] D. S. Chang, E. Hsu, D. G. Hottinger, and S. P. Cohen, “Anti-nerve Growth Factor in Pain Management: Current Evidence,” J Pain Res 9 (2016): 373–383.

[197] M. Schmelz, P. Mantyh, A. M. Malfait, et al., “Nerve Growth Factor Antibody for the Treatment of Osteoarthritis Pain and Chronic Low-back Pain: Mechanism of Action in the Context of Efficacy and Safety,” Pain 160, no. 10 (2019): 2210–2220.

[198] B. L. Wise, M. F. Seidel, and N. E. Lane, “The Evolution of Nerve Growth Factor Inhibition in Clinical Medicine,” Nat Rev Rheumatol 17, no. 1 (2021): 34–46.

[199] M. Fallon, M. Sopata, E. Dragon, et al., “A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects with Cancer Pain due to Bone Metastasis,” The Oncologist 28, no. 12 (2023): e1268–e1278.

[200] M. Hartel, F. F. di Mola, F. Selvaggi, et al., “Vanilloids in Pancreatic Cancer: Potential for Chemotherapy and Pain Management,” Gut 55, no. 4 (2006): 519–528.

[201] D. C. Brown, K. Agnello, and M. J. Iadarola, “Intrathecal Resiniferatoxin in a Dog Model: Efficacy in Bone Cancer Pain,” Pain 156, no. 6 (2015): 1018–1024.

[202] A. Szallasi, “Targeting TRPV1 for Cancer Pain Relief: Can It Work?,” Cancers (Basel) 16, no. 3 (2024).

[203] A. Szallasi, “Resiniferatoxin: Nature's Precision Medicine to Silence TRPV1-Positive Afferents,” International Journal of Molecular Sciences 24, no. 20 (2023).

[204] D. C. Brown, “Resiniferatoxin: The Evolution of the , “Molecular Scalpel” for Chronic Pain Relief,” Pharmaceuticals (Basel) 9, no. 3 (2016).

[205] N. N. Lam, P. Q. Khanh, and N. H. An, “The Use of Propranolol in Adult Burn Patients: Safety and Outcome Influence,” Burns 48, no. 4 (2022): 767–773.

[206] F. N. Ågesen, P. E. Weeke, P. Tfelt-Hansen, and J. Tfelt-Hansen, “Pharmacokinetic Variability of Beta-adrenergic Blocking Agents Used in Cardiology,” Pharmacol Res Perspect 7, no. 4 (2019): e00496.

[207] C. Droitcourt, S. Kerbrat, C. Rault, et al., “Safety of Oral Propranolol for Infantile Hemangioma,” Pediatrics 141, no. 6 (2018).

[208] D. Liu, J. Flory, and A. Lin, “Characterization of on-target Adverse Events Caused by TRK Inhibitor Therapy,” Annals of Oncology 31, no. 9 (2020): 1207–1215.

[209] C. Yang, Y. He, F. Chen, F. Zhang, D. Shao, and Z. Wang, “Leveraging β-Adrenergic Receptor Signaling Blockade for Improved Cancer Immunotherapy through Biomimetic Nanovaccine,” Small 19, no. 14 (2023): e2207029.

[210] J. Qin, J. Liu, Z. Wei, et al., “Targeted Intervention in Nerve-cancer Crosstalk Enhances Pancreatic Cancer Chemotherapy,” Nature Nanotechnology (2024).

[211] F. Li, C. He, H. Yao, et al., “Glutamate From Nerve Cells Promotes Perineural Invasion in Pancreatic Cancer by Regulating Tumor Glycolysis Through HK2 mRNA-m6A Modification,” Pharmacological Research 187 (2023): 106555.

[212] S. S. Hallan, J. Amirian, A. Brangule, and D. Bandere, “Lipid-Based Nano-Sized Cargos as a Promising Strategy in Bone Complications: A Review,” Nanomaterials (Basel) 12, no. 7 (2022).

[213] L. Shaashua, M. Shabat-Simon, R. Haldar, et al., “Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial,” Clinical Cancer Research 23, no. 16 (2017): 4651–4661.

[214] S. Sivanesan, K. A. Taskén, and H. H. Grytli, “Association of β-Blocker Use at Time of Radical Prostatectomy with Rate of Treatment for Prostate Cancer Recurrence,” JAMA Network Open 5, no. 1 (2022): e2145230.

[215] G. Spera, R. Fresco, H. Fung, et al., “Beta Blockers and Improved Progression-free Survival in Patients With Advanced HER2 Negative Breast Cancer: A Retrospective Analysis of the ROSE/TRIO-012 Study,” Annals of Oncology 28, no. 8 (2017): 1836–1841.

[216] L. Zhou, Y. Li, X. Li, et al., “Propranolol Attenuates Surgical Stress-Induced Elevation of the Regulatory T Cell Response in Patients Undergoing Radical Mastectomy,” Journal of Immunology 196, no. 8 (2016): 3460–3469.

[217] F. Heitz, du A. Bois, P. Harter, et al., “Impact of Beta Blocker Medication in Patients With Platinum Sensitive Recurrent Ovarian Cancer-a Combined Analysis of 2 Prospective Multicenter Trials by the AGO Study Group, NCIC-CTG and EORTC-GCG,” Gynecologic Oncology 129, no. 3 (2013): 463–466.

[218] Y. L. Hwa, Q. Shi, S. K. Kumar, et al., “Beta-blockers Improve Survival Outcomes in Patients With Multiple Myeloma: A Retrospective Evaluation,” American Journal of Hematology 92, no. 1 (2017): 50–55.

[219] P. Y. Chang, W. Y. Huang, C. L. Lin, et al., “Propranolol Reduces Cancer Risk: A Population-Based Cohort Study,” Medicine 94, no. 27 (2015): e1097.

[220] A. Embaby, K. M. Heinhuis, N. S. IJ, et al., “Propranolol Monotherapy in Angiosarcoma—A Window-of-opportunity Study (PropAngio),” European Journal of Cancer 202 (2024): 113974.

[221] F. J. Hüttner, R. Klotz, N. A. Giese, et al., “Pancreatic Resection With Perioperative Drug Repurposing of Propranolol and Etodolac—the Phase II Randomized Controlled PROSPER Trial,” Langenbecks Archives of Surgery 410, no. 1 (2025): 168.

[222] M. B. Hopson, S. Lee, M. Accordino, et al., “Phase II Study of Propranolol Feasibility With Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,” Breast Cancer Research and Treatment 188, no. 2 (2021): 427–432.

[223] S. Gandhi, M. R. Pandey, K. Attwood, et al., “Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity,” Clinical Cancer Research 27, no. 1 (2021): 87–95.

[224] L. M. Ramondetta, W. Hu, P. H. Thaker, et al., “Prospective Pilot Trial With Combination of Propranolol With Chemotherapy in Patients With Epithelial Ovarian Cancer and Evaluation on Circulating Immune Cell Gene Expression,” Gynecologic Oncology 154, no. 3 (2019): 524–530.

[225] S. R. Rapp, E. V. Dressler, W. M. Brown, et al., “Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors after Adjuvant Chemotherapy (WF-97116),” Journal of Clinical Oncology 42, no. 21 (2024): 2546–2557.

[226] J. A. Lawrence, L. Griffin, E. P. Balcueva, et al., “A Study of donepezil in Female Breast Cancer Survivors With Self-reported Cognitive Dysfunction 1 to 5 Years Following Adjuvant Chemotherapy,” J Cancer Surviv 10, no. 1 (2016): 176–184.

[227] R. A. White, V. Mezzano-Robinson, Q. Shi, et al., “A Phase 0, Window of Opportunity Study of Parasympathetic Stimulation With Bethanechol in Localized Pancreatic Adenocarcinoma Prior to Surgery,” The Oncologist 30, no. 6 (2025).

[228] A. J. Mannes, J. D. Heiss, A. Berger, et al., “Treatment of Intractable Cancer Pain With Resiniferatoxin—An Interim Study,” NEJM Evid 4, no. 6 (2025): EVIDoa2400423.

[229] Q. Lin, S. Zheng, X. Yu, et al., “Standard Pancreatoduodenectomy versus Extended Pancreatoduodenectomy With Modified Retroperitoneal Nerve Resection in Patients With Pancreatic Head Cancer: A Multicenter Randomized Controlled Trial,” Cancer Commun (Lond) 43, no. 2 (2023): 257–275.

[230] K. Guber and A. J. Kirtane, “Renal Sympathetic Denervation for Hypertension,” Kidney Int Rep 7, no. 10 (2022): 2129–2140.

[231] H. Krum, M. Schlaich, R. Whitbourn, et al., “Catheter-based Renal Sympathetic Denervation for Resistant Hypertension: A Multicentre Safety and Proof-of-principle Cohort Study,” Lancet 373, no. 9671 (2009): 1275–1281.

[232] A. R. Tzafriri, F. Garcia-Polite, J. Keating, et al., “Morphometric Analysis of the human Common Hepatic Artery Reveals a Rich and Accessible Target for Sympathetic Liver Denervation,” Scientific Reports 12, no. 1 (2022): 1413.

[233] A. R. Tzafriri, F. Garcia-Polite, J. Keating, et al., “Correction: Morphometric Analysis of the human Common Hepatic Artery Reveals a Rich and Accessible Target for Sympathetic Liver Denervation,” Scientific Reports 15, no. 1 (2025): 28785.

[234] J. O'Logbon, L. Tarantola, N. R. Williams, S. Mehta, A. Ahmed, and E. A. Davies, “Does Propranolol Have a Role in Cancer Treatment? A Systematic Review of the Epidemiological and Clinical Trial Literature on Beta-blockers,” Journal of Cancer Research and Clinical Oncology 151, no. 7 (2025): 212.

[235] M. S. Oh, A. Guzner, D. A. Wainwright, et al., “The Impact of Beta Blockers on Survival Outcomes in Patients with Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors,” Clinical Lung Cancer 22, no. 1 (2021): e57–e62.

[236] M. M. Chen, Q. Gao, H. Ning, et al., “Integrated Single-cell and Spatial Transcriptomics Uncover Distinct Cellular Subtypes Involved in Neural Invasion in Pancreatic Cancer,” Cancer Cell (2025).

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.